These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36893014)

  • 1. Tumor Microenvironment and Its Clinicopathologic and Prognostic Association in Cutaneous and Noncutaneous Angiosarcomas.
    Machado I; Requena C; López-Reig R; Fernández-Serra A; Giner F; Cruz J; Traves V; Lavernia J; Claramunt R; Llombart B; López-Guerrero JA; Llombart-Bosch A
    Am J Clin Pathol; 2023 Jul; 160(1):18-34. PubMed ID: 36893014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
    Googe PB; Flores K; Jenkins F; Merritt B; Moschos SJ; Grilley-Olson JE
    Am J Dermatopathol; 2021 Aug; 43(8):556-559. PubMed ID: 33156018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites.
    Ginter PS; Mosquera JM; MacDonald TY; D'Alfonso TM; Rubin MA; Shin SJ
    Hum Pathol; 2014 Apr; 45(4):709-16. PubMed ID: 24457083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression.
    Fraga-Guedes C; André S; Mastropasqua MG; Botteri E; Toesca A; Rocha RM; Peradze N; Rotmensz N; Viale G; Veronesi P; Gobbi H
    Breast Cancer Res Treat; 2015 May; 151(1):131-40. PubMed ID: 25893585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.
    Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z
    Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast.
    Kuba MG; Xu B; D'Angelo SP; Rosenbaum E; Plitas G; Ross DS; Brogi E; Antonescu CR
    Histopathology; 2021 Nov; 79(5):836-846. PubMed ID: 34165212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and Fluorescence In Situ Hybridization Analysis of MYC in a Series of 17 Cutaneous Angiosarcomas: A Single-Center Study.
    Requena C; Rubio L; Lavernia J; Machado I; Llombart B; Sanmartín O; Traves V; Guillén C; Cruz J
    Am J Dermatopathol; 2018 May; 40(5):349-354. PubMed ID: 29135507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases.
    Mentzel T; Schildhaus HU; Palmedo G; Büttner R; Kutzner H
    Mod Pathol; 2012 Jan; 25(1):75-85. PubMed ID: 21909081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
    Ghiringhelli F; Bibeau F; Greillier L; Fumet JD; Ilie A; Monville F; Laugé C; Catteau A; Boquet I; Majdi A; Morgand E; Oulkhouir Y; Brandone N; Adam J; Sbarrato T; Kassambara A; Fieschi J; Garcia S; Lepage AL; Tomasini P; Galon J
    EBioMedicine; 2023 Jun; 92():104633. PubMed ID: 37244159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study.
    Shon W; Sukov WR; Jenkins SM; Folpe AL
    Mod Pathol; 2014 Apr; 27(4):509-15. PubMed ID: 24091875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis.
    Lobrano R; Paliogiannis P; Zinellu A; Palmieri G; Persico I; Mangoni AA; Cossu A
    Curr Oncol; 2023 May; 30(5):5135-5144. PubMed ID: 37232846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC gene amplification by fluorescence in situ hybridization and MYC protein expression by immunohistochemistry in the diagnosis of cutaneous angiosarcoma: Systematic review and appropriate use criteria.
    Motaparthi K; Lauer SR; Patel RM; Vidal CI; Linos K
    J Cutan Pathol; 2021 Apr; 48(4):578-586. PubMed ID: 33128474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
    Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
    Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
    Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
    J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PD-L1 expression in cutaneous angiosarcoma : Systematic review with meta-anakysis].
    Harbrücker M; Reißfelder C; Jakob J
    Chirurgie (Heidelb); 2024 Sep; 95(9):766-767. PubMed ID: 39014222
    [No Abstract]   [Full Text] [Related]  

  • 18. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
    Italiano A; Thomas R; Breen M; Zhang L; Crago AM; Singer S; Khanin R; Maki RG; Mihailovic A; Hafner M; Tuschl T; Antonescu CR
    Genes Chromosomes Cancer; 2012 Jun; 51(6):569-78. PubMed ID: 22383169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
    Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
    Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.